ClinicalTrials.gg
CompletedNCT04440345Updated Nov 28, 2023

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

A Phase 1/2 interventional study of IBI362 and Placebo in Overweight or Obesity, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Enrollment
18th of 22
60 · median 187
Started
2020
the only one that year
Phase 1/2
2 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
12 of 22
Innovent Biologics (Suzhou) Co. Ltd.

Among the 22 studies testing mazdutide in Obesity, this one is the 18th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 60 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have stable body weight for the past 12 weeks prior to screening
  2. Have a (BMI) ≥24 kilograms per meter squared (kg/m²) with complication, or BMI≥28 kg/m²,inclusive at screening
  3. Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff

Exclusion criteria

Exclusion Criteria:

  1. Have a diagnosis of type 2 diabetes
  2. Have received prescription drugs or over the counter drugs that promote weight loss in the past 3 months prior to screening
  3. Previous treatment with a GLP-1 (glucagon-like peptide 1) receptor agonists or GCG(glucagon)receptor agonists before.
  4. Surgical treatment for obesity
  5. Past or current chronic or idiopathic pancreatitis, or any of the following: -amylase or lipase above 2 times UNR (upper normal range), triglycerides above 500 mg/dL
  6. Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study
  7. Unwilling to comply with smoking and alcohol restrictions during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IBI362

    Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses. Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses.

    Drug: IBI362

  • Placebo comparator
    placebo

    Participants received matching placebo dose regiments by subcutaneous injection

    Drug: Placebo

Interventions

  • DrugIBI362

    Administered by subcutaneous injection

  • DrugPlacebo

    Administered by subcutaneous injection

07

What researchers measure

Primary outcomes

  1. Number of treatment adverse events

    The relationship of each adverse event to the investigational product was assessed by the investigator.

    Time frame: From the time of first dosing (Day 1 ) until completion of the post treatment follow-up visit (20 week)

Secondary outcomes

  1. Number of Participants With Anti-IBI362 Antibodies

    Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-IBI362 binding antibodies. Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-IBI362 neutralizing antibodies.

    Time frame: From the time of first dosing (Day 1 )until comletion of the post treatment follow-up visit (20 week)

  2. Evaluate the Peak Plasma Concentration (Cmax) of IBI362 in overweight or obesity subjects;

    Time frame: From the first dose (Day 1 ) of study drug until 12 week

  3. Evaluate the Area under the plasma concentration versus time curve (AUC) of IBI362 in overweight or obesity subjects;

    Time frame: From the first dose (Day 1 ) of study drug until 12 week

  4. Evaluate the Fasting Blood Glucose (FBG ) of IBI362 in overweight or obesity subjects;

    Time frame: From the first dose (Day 1 ) of study drug until 12 week

  5. Evaluate the Glucagon of IBI362 in overweight or obesity subjects;

    Time frame: From the first dose (Day 1 ) of study drug until 12 week

  6. Evaluate the Insulin of IBI362 in overweight or obesity subjects;

    Time frame: From the first dose (Day 1 ) of study drug until 12 week

  7. Evaluate the C-peptide of IBI362 in overweight or obesity subjects;

    Time frame: From the first dose (Day 1 ) of study drug until 12 week

  8. Change in body weight from baseline

    Time frame: Baseline (Day 1 ) and 12 week for groups

08

Study locations

1 site
  • Peking University people's hospital
    Beijing, China
09

References and documents

Publications

  • Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, Cai C, Deng H, Feng L, Song B, Ma Q, Qian L. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022 Oct 7;54:101691. doi: 10.1016/j.eclinm.2022.101691. eCollection 2022 Dec. PubMed 36247927 ↗
  • Ji L, Jiang H, An P, Deng H, Liu M, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021 Aug 13;39:101088. doi: 10.1016/j.eclinm.2021.101088. eCollection 2021 Sep. PubMed 34430840 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jun 2021, 12 months.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2020
First posted
Jun 19, 2020
StartActual
Jun 16, 2020
Primary completionActual
Jun 16, 2021
CompletionActual
Aug 6, 2021
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04440345
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Jun 16, 2020
Primary completion
Jun 16, 2021
Completion
Aug 6, 2021
Last update
Nov 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion